Roche Diagnostics Announces $550 Million Expansion in Indianapolis, Strengthening U.S. Manufacturing and Health Innovation
Indianapolis continues to lead as a national hub for life sciences innovation and advanced manufacturing. On Monday, Roche Diagnostics announced it will invest up to $550 million in its Indianapolis-based operations over the next five years, adding hundreds of skilled jobs and establishing the city as a global manufacturing center for the company’s continuous glucose monitoring (CGM) system.
The announcement, made on Roche’s North American campus on the northeast side of Indianapolis, drew civic and business leaders—including Mayor Joe Hogsett and Indy Economic Development CEO James Schellinger—to celebrate this milestone investment.
“This is more than a manufacturing expansion,” said Roche Diagnostics North America CEO Brad Moore. “It’s a commitment to patients, to innovation, and to Indianapolis as a long-term partner in solving one of the most pressing health challenges of our time: diabetes.”
A Commitment to Domestic Manufacturing and Public Health
The investment will enable Roche to build and scale a state-of-the-art CGM manufacturing facility, part of the company’s broader global effort to meet rising demand for diabetes care. With over 38 million Americans living with diabetes, this technology is increasingly critical for real-time monitoring and management.
In addition to creating hundreds of new full-time roles in advanced manufacturing, the project is expected to generate thousands of construction jobs. It also aligns with broader national efforts to expand domestic production capacity and reduce dependence on international supply chains.
A Strategic Site for Global Operations
Roche’s Indianapolis campus currently employs 4,815 people and already serves as one of two global distribution hubs for the company, supporting shipments to 53 countries. It is also home to research and development, laboratories, distribution, IT, and corporate functions.
“When looking at where to make this major investment, Indianapolis stood out,” said Richeal Cline, Global Head of Operations for Roche Diagnostics. “The talent, infrastructure, and existing presence here made this the natural choice.”
Fueling Indiana’s Life Sciences Economy
Roche’s expansion adds to the momentum of Indiana’s growing life sciences sector, which contributes more than $80 billion annually to the state economy. It follows other significant investment announcements, including Eli Lilly and Co.’s recent $27 billion commitment to new U.S. manufacturing facilities.
At Indy Economic Development, we are proud to support Roche Diagnostics in this next chapter of growth. This investment reflects the confidence global companies continue to place in Indianapolis as a city where innovation, talent, and infrastructure intersect.
Stay tuned for more updates as this transformative project moves forward.
